Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Raphael Pharmaceutical Inc. (RAPH) had Consolidated Net Income/Loss of $-0.42M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.43M |
|
-- |
|
-- |
|
$0.42M |
|
$-0.42M |
|
$0.00M |
|
$-0.42M |
|
$-0.42M |
|
$-0.42M |
|
$-0.42M |
|
|
Consolidated Net Income/Loss |
$-0.42M |
$-0.42M |
|
$-0.42M |
|
$-0.42M |
|
19.63M |
|
19.63M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$0.09M |
|
$0.00M |
|
$0.00M |
|
$0.09M |
|
$0.83M |
|
-- |
|
-- |
|
$0.83M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
19.63M |
|
| Cash Flow Statement Financials | |
$-0.21M |
|
-- |
|
$0.24M |
|
$0.02M |
|
$0.05M |
|
$0.03M |
|
$0.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.11 |
|
-- |
|
-- |
|
-- |
|
-0.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
57.36% |
|
57.36% |
|
-452.69% |
|
57.36% |
|
$-0.04 |
|
$-0.01 |
|
$-0.01 |
|